BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30425091)

  • 1. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
    Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
    Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer.
    Elfar GA; Ebrahim MA; Elsherbiny NM; Eissa LA
    Oncol Res; 2017 Apr; 25(4):641-650. PubMed ID: 27983911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
    Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
    Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females.
    Shaker OG; Elbaz EM
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):355-361. PubMed ID: 32102511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Kawamura K; Imamoto T; Takanami M; Ichikawa T
    Int J Clin Oncol; 2011 Aug; 16(4):366-72. PubMed ID: 21327451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone metastases detection by circulating biomarkers: OPG and RANK-L.
    Mercatali L; Ibrahim T; Sacanna E; Flamini E; Scarpi E; Calistri D; Ricci M; Serra P; Ricci R; Zoli W; Kang Y; Amadori D
    Int J Oncol; 2011 Jul; 39(1):255-61. PubMed ID: 21491082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
    Shaker OG; Helmy HS
    Clin Breast Cancer; 2018 Jun; 18(3):e321-e328. PubMed ID: 28645722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
    Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
    Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegerin levels and mammographic density among high-risk women.
    Moran O; Zaman T; Eisen A; Demsky R; Blackmore K; Knight JA; Elser C; Ginsburg O; Zbuk K; Yaffe M; Narod SA; Salmena L; Kotsopoulos J
    Cancer Causes Control; 2018 Jun; 29(6):507-517. PubMed ID: 29679262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.